Leerink Partners Issues Positive Forecast for Insulet (NASDAQ:PODD) Stock Price

Key Points

• Leerink Partners raised its target price for Insulet (NASDAQ:PODD) from $339.00 to $355.00, indicating a potential upside of 13.42% from its current price.
• Insulet's stock has received positive ratings from multiple analysts, with a consensus rating of "Moderate Buy" and an average price target of $348.05.
• Insulet reported strong quarterly results with revenues of $649.1 million, exceeding analysts' expectations, and a significant year-over-year growth of 32.9% in revenue.

Insulet (NASDAQ:PODD - Get Free Report) had its target price lifted by equities researchers at Leerink Partners from $339.00 to $355.00 in a report released on Tuesday,MarketScreener reports. The firm presently has an "outperform" rating on the medical instruments supplier's stock. Leerink Partners' price objective would suggest a potential upside of 13.42% from the company's current price.

Other equities research analysts have also recently issued reports about the company. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Insulet in a research note on Wednesday, October 8th. Oppenheimer upped their target price on shares of Insulet from $324.00 to $365.00 and gave the stock an "outperform" rating in a research note on Monday, September 8th. Wells Fargo & Company lifted their price objective on shares of Insulet from $330.00 to $350.00 and gave the stock an "overweight" rating in a research report on Friday, August 8th. Royal Bank Of Canada upped their price target on Insulet from $350.00 to $365.00 and gave the company an "outperform" rating in a report on Friday. Finally, Barclays upped their target price on Insulet from $266.00 to $300.00 and gave the company an "equal weight" rating in a research report on Thursday, August 21st. Eighteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $348.05.

Insulet Stock Down 0.5%

Shares of NASDAQ:PODD opened at $312.99 on Tuesday. Insulet has a 52-week low of $226.50 and a 52-week high of $353.50. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The business has a fifty day moving average of $324.28 and a two-hundred day moving average of $301.03. The stock has a market cap of $22.03 billion, a P/E ratio of 95.31, a PEG ratio of 2.61 and a beta of 1.40.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm had revenue of $649.10 million during the quarter, compared to analysts' expectations of $612.31 million. During the same period last year, the business earned $0.55 earnings per share. Insulet's revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, research analysts expect that Insulet will post 3.92 earnings per share for the current year.

Insiders Place Their Bets

In other Insulet news, SVP Prem Singh sold 687 shares of the stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the transaction, the senior vice president directly owned 3,456 shares of the company's stock, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the transaction, the senior vice president directly owned 3,890 shares of the company's stock, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Insulet

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PODD. Larson Financial Group LLC increased its stake in shares of Insulet by 426.3% during the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock worth $26,000 after purchasing an additional 81 shares in the last quarter. Zions Bancorporation National Association UT purchased a new stake in shares of Insulet in the first quarter valued at $26,000. SouthState Corp boosted its stake in shares of Insulet by 253.3% during the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock valued at $28,000 after acquiring an additional 76 shares during the last quarter. Kozak & Associates Inc. acquired a new position in Insulet in the 2nd quarter valued at about $32,000. Finally, Golden State Wealth Management LLC boosted its stake in shares of Insulet by 202.9% during the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier's stock worth $32,000 after purchasing an additional 69 shares during the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.